Fycompa (perampanel; Eisai) is a selective, non-competitive, alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist that exhibits antiseizure activity by reducing glutamatergic signaling. Eisai has solely developed Fycompa and now markets it as a once-daily oral anticonvulsant for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. Additionally, Eisai is seeking to expand Fycompa’s use to pediatric patients, and has previously conducted monotherapy studies and investigated the drug in Lennox-Gastaut syndrome.
Fycompa (perampanel; Eisai) looks set to address a key unmet need through the demonstration of efficacy in drug-resistant epilepsy patients. Approved in the US, EU, and Japan as an adjunctive treatment for partial-onset epilepsy and primary generalized tonic-clonic (PGTC) seizures, it also acts via a novel mechanism of action and has once-daily dosing. These factors, along with its ability to treat patients resistant to current pharmacological therapies, serve as key clinical differentiators for Fycompa. Given that it is competing for market share with multiple other anti-epileptic drugs (AEDs) approved for refractory partial seizures and PGTC seizures in highly genericized and competitive markets, Eisai should continually seek to maximize its commercial opportunity with Fycompa by acquiring approval in additional indications.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Fycompa : Epilepsy
LIST OF FIGURES
311 Figure 1: Fycompa for epilepsy – SWOT analysis
12 Figure 2: Datamonitor Healthcare’s drug assessment summary for Fycompa in epilepsy
13 Figure 3: Datamonitor Healthcare’s drug assessment summary for Fycompa in epilepsy
LIST OF TABLES
4 Table 1: Fycompa epilepsy indication approvals
4 Table 2: Fycompa drug profile
7 Table 3: Fycompa pivotal trial data in epilepsy
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.